Vendor review
EHZ Peptides reviews
EHZ Peptides reviews from 73 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is EHZ Peptides legit? See what its vials showed.
Grade A73 independent lab tests0 peptides listed
What the lab tests show
73 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 8, 2026 | Cagrilintide | 99.9 % | 2.81 mg of 5 mg (-44 %) | Pass | View |
| Oct 6, 2026 | Retatrutide | 100 % | 44.6564 mg of 30 mg (49 %) | Pass | View |
| Oct 1, 2026 | Tirzepatide | 99.9 % | 14.99 mg of 15 mg (0 %) | Pass | View |
| Sep 30, 2026 | Retatrutide | 99.9 % | 29.99 mg of 30 mg (0 %) | Pass | View |
| Sep 17, 2026 | Retatrutide | 20 mg | Fail | View | |
| Sep 14, 2026 | Retatrutide | 99.8 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Sep 10, 2026 | Tesamorelin | 95.9 % | 8.41 mg of 10 mg (-16 %) | Pass | View |
| Sep 9, 2026 | GHK-Cu | 99.9 % | 60.7 mg of 100 mg (-39 %) | Pass | View |
| Sep 9, 2026 | BPC-157 | 99.9 % | 8.62 mg of 10 mg (-14 %) | Pass | View |
| Sep 7, 2026 | Retatrutide | 99.8 % | 20.1 mg of 20 mg (1 %) | Pass | View |
| Aug 6, 2026 | Retatrutide | 99.8 % | 16.5 mg of 15 mg (10 %) | Pass | View |
| Jul 21, 2026 | Tesamorelin | 99.9 % | 20.7 mg of 15 mg (38 %) | Pass | View |
| Jul 17, 2026 | Retatrutide | 99.9 % | 9.75 mg of 10 mg (-3 %) | Pass | View |
| Jul 13, 2026 | Tesamorelin | 98.8 % | 15.7 mg of 10 mg (57 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 99.9 % | 18.3 mg of 15 mg (22 %) | Pass | View |
| Jul 13, 2026 | GHK-Cu | 99.9 % | 39.9 mg of 50 mg (-20 %) | Pass | View |
| Jul 13, 2026 | BPC-157 | 99.9 % | 1.94 mg of 10 mg (-81 %) | Pass | View |
| Jun 16, 2026 | Retatrutide | 99.7 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 20.8 mg of 20 mg (4 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.9 % | 17.8 mg of 15 mg (19 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 99.9 % | 59.4 mg of 50 mg (19 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 99.9 % | 96.4 mg of 100 mg (-4 %) | Pass | View |
| Mar 6, 2026 | BPC-157 | 99.9 % | 9.54 mg of 10 mg (-5 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.7 % | 13.8 mg of 15 mg (-8 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.83 % | 31.3 mg of 30 mg (4 %) | Pass | View |
| Feb 20, 2026 | Tesamorelin | 98.53 % | 5.65 mg of 5 mg (13 %) | Pass | View |
| Feb 20, 2026 | Tesamorelin | 98.97 % | 5.74 mg of 5 mg (15 %) | Pass | View |
| Feb 18, 2026 | Cagrilintide | 97.16 % | 5.14 mg of 5 mg (3 %) | Pass | View |
| Feb 15, 2026 | Retatrutide | 99.8 % | 49.7 mg of 50 mg (-1 %) | Pass | View |
| Feb 10, 2026 | Retatrutide | 99.8 % | 32.9 mg of 30 mg (10 %) | Pass | View |
| Feb 10, 2026 | GHK-Cu | 99.8 % | 82.9 mg of 100 mg (-17 %) | Pass | View |
| Feb 10, 2026 | BPC-157 | 99.4 % | 5.5 mg of 10 mg (-45 %) | Pass | View |
| Feb 10, 2026 | Tirzepatide | 99.8 % | 54.5 mg of 60 mg (-9 %) | Pass | View |
| Feb 9, 2026 | Retatrutide | 99.9 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Feb 4, 2026 | Cagrilintide | 99.8 % | 12 mg of 10 mg (20 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.8 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Jan 26, 2026 | BPC-157 | 98.2 % | 11.5 mg of 10 mg (15 %) | Pass | View |
| Jan 26, 2026 | Tirzepatide | 99.8 % | 22.1 mg of 20 mg (11 %) | Pass | View |
| Jan 26, 2026 | Retatrutide | 99.7 % | 15.2 mg of 15 mg (1 %) | Pass | View |
| Jan 9, 2026 | Tirzepatide | 99.95 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Jan 7, 2026 | Retatrutide | 99.95 % | 16 mg of 15 mg (7 %) | Pass | View |
| Jan 7, 2026 | Retatrutide | 99.8 % | 34.2 mg of 30 mg (14 %) | Pass | View |
| Jan 7, 2026 | Retatrutide | 99.24 % | 4.96 mg of 5 mg (-1 %) | Pass | View |
| Dec 17, 2025 | Retatrutide | 99.75 % | 30 mg of 30 mg (0 %) | Pass | View |
| Dec 17, 2025 | Retatrutide | 99.83 % | 19.7 mg of 20 mg (-2 %) | Pass | View |
| Dec 17, 2025 | GHK-Cu | 100 mg | Fail | View | |
| Dec 13, 2025 | Retatrutide | 99.6 % | 33.1 mg of 30 mg (10 %) | Pass | View |
| Dec 13, 2025 | Tirzepatide | 99.6 % | 34.2 mg of 30 mg (14 %) | Pass | View |
| Dec 13, 2025 | Tirzepatide | 99.3 % | 14.7 mg of 40 mg (-63 %) | Pass | View |
| Dec 13, 2025 | Tirzepatide | 99.3 % | 46.5 mg of 40 mg (16 %) | Pass | View |
| Dec 13, 2025 | Retatrutide | 99.7 % | 32.9 mg of 30 mg (10 %) | Pass | View |
| Oct 29, 2025 | GHK-Cu | 99.92 % | 55.8 mg of 50 mg (12 %) | Pass | View |
| Oct 23, 2025 | Tesamorelin | 99.95 % | 4.25 mg of 5 mg (-15 %) | Pass | View |
| Oct 23, 2025 | Retatrutide | 99.9 % | 30.7 mg of 30 mg (2 %) | Pass | View |
| Oct 21, 2025 | Retatrutide | 99.7 % | 32 mg of 30 mg (7 %) | Pass | View |
| Oct 14, 2025 | Tirzepatide | 99.7 % | 32.9 mg of 30 mg (10 %) | Pass | View |
| Oct 14, 2025 | BPC-157 | 99.8 % | 5.8 mg of 5 mg (16 %) | Pass | View |
| Oct 13, 2025 | Tirzepatide | 99.7 % | 29.9 mg of 30 mg (0 %) | Pass | View |
| Oct 13, 2025 | Retatrutide | 99.7 % | 23.9 mg of 20 mg (20 %) | Pass | View |
| Oct 13, 2025 | Retatrutide | 99.8 % | 36.4 mg of 30 mg (21 %) | Pass | View |
What EHZ Peptides sells
No current listings on record.
About EHZ Peptides
Finnrick has tested 73 samples from EHZ Peptides across 6 products.